Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Milestone Pharmaceuticals Inc. (MIST : NSDQ)

• Company Description    Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $1.52 Daily Weekly Monthly 20 Day Moving Average: 2,272,085 shares Shares Outstanding: 117.67 (millions) Market Capitalization: $178.85 (millions) Beta: 0.69 52 Week High: $3.06 52 Week Low: $0.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.98% -6.45% 12 Week -22.45% -18.16% Year To Date -24.75% -22.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1111 DR. FREDERIK-PHILIPS BOULEVARD SUITE 420 - MONTREAL,A8 H4M 2X6 CAN ph: 514-336-0444 fax: - kgardner@lifesciadvisors.com http://www.milestonepharma.com

• General Corporate Information    Officers Joseph Oliveto - Chief Executive Officer and Director Robert Wills - Chairman of the Board Amit Hasija - Chief Financial Officer Seth Fischer - Director Lisa M. Giles - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 59935V107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/13/26 Share - Related Items Shares Outstanding: 117.67 Most Recent Split Date: (:1) Beta: 0.69 Market Capitalization: $178.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.87 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 15.79% vs. Previous Quarter: -33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - -656.73 09/30/25 - -2,374.19 ROA 03/31/26 - - 12/31/25 - -81.19 09/30/25 - -85.19 Current Ratio 03/31/26 - - 12/31/25 - 8.01 09/30/25 - 8.24 Quick Ratio 03/31/26 - - 12/31/25 - 7.96 09/30/25 - 8.24 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - -4,078.78 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - 0.39 09/30/25 - 0.24 Inventory Turnover 03/31/26 - - 12/31/25 - 0.00 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 1.37 09/30/25 - 2.74 Debt-to-Capital 03/31/26 - - 12/31/25 - 57.79 09/30/25 - 73.27

Powered by Zacks Investment Research ©